Telitacicept for systemic lupus erythematosus: protocol of a systematic review and meta-analysis
Introduction Systemic lupus erythematosus (SLE) is a chronic and complex multisystem autoimmune disease with high mortality. Telitacicept is a new strategy for the treatment of SLE, inhibiting the maturity, proliferation and differentiation of B cells, and thus, reduces disease activity. However, th...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-07-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/15/7/e090646.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849715633086791680 |
|---|---|
| author | Xin Yu Jiawei Zhang Xiangge Ren Peidong Zhao Wensheng Zhai |
| author_facet | Xin Yu Jiawei Zhang Xiangge Ren Peidong Zhao Wensheng Zhai |
| author_sort | Xin Yu |
| collection | DOAJ |
| description | Introduction Systemic lupus erythematosus (SLE) is a chronic and complex multisystem autoimmune disease with high mortality. Telitacicept is a new strategy for the treatment of SLE, inhibiting the maturity, proliferation and differentiation of B cells, and thus, reduces disease activity. However, the effectiveness and safety of telitacicept in patients with SLE are not yet established.Methods and analysis Five English databases (Pubmed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, Cumulative Index of Nursing and Allied Health Literature) and four Chinese databases (China National Knowledge Infrastructure, Wanfang Data, China Science and Technology Journal Database and Sinomed) will be searched from database inception to 1 June 2025. Two investigators will independently conduct study selection, data extraction and quality assessment. Outcomes include disease activity, incidence of flares, organ damage, several immune-related laboratory parameters and adverse events. Risk ratio with 95% CI and mean difference or standardised mean difference will be used as measures of effect sizes, in order to pool the data using either a random-effect model or fixed-effect model according to the heterogeneity of studies. Subgroup analysis and sensitivity analysis will be performed to explore the source of heterogeneity and evaluate the robustness of the results. We will use the Risk of Bias 2 tool and Risk of Bias In Non-Randomized Studies of Interventions tools to assess the quality of the included studies, and use the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) system to assess the certainty of evidence.Ethics and dissemination No ethical approval is required since this review is based on previously published studies. The findings of this study will be presented at international conferences or published in a peer-reviewed journal.PROSPERO registration number CRD42024558180. |
| format | Article |
| id | doaj-art-3ac9d93fcaa242e4af90a78fd2aa886b |
| institution | DOAJ |
| issn | 2044-6055 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-3ac9d93fcaa242e4af90a78fd2aa886b2025-08-20T03:13:18ZengBMJ Publishing GroupBMJ Open2044-60552025-07-0115710.1136/bmjopen-2024-090646Telitacicept for systemic lupus erythematosus: protocol of a systematic review and meta-analysisXin Yu0Jiawei Zhang1Xiangge Ren2Peidong Zhao3Wensheng Zhai4Department of Pediatrics, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, ChinaDepartment of Pediatrics, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, ChinaDepartment of Pediatrics, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, ChinaDepartment of Pediatrics, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, ChinaDepartment of Pediatrics, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, ChinaIntroduction Systemic lupus erythematosus (SLE) is a chronic and complex multisystem autoimmune disease with high mortality. Telitacicept is a new strategy for the treatment of SLE, inhibiting the maturity, proliferation and differentiation of B cells, and thus, reduces disease activity. However, the effectiveness and safety of telitacicept in patients with SLE are not yet established.Methods and analysis Five English databases (Pubmed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, Cumulative Index of Nursing and Allied Health Literature) and four Chinese databases (China National Knowledge Infrastructure, Wanfang Data, China Science and Technology Journal Database and Sinomed) will be searched from database inception to 1 June 2025. Two investigators will independently conduct study selection, data extraction and quality assessment. Outcomes include disease activity, incidence of flares, organ damage, several immune-related laboratory parameters and adverse events. Risk ratio with 95% CI and mean difference or standardised mean difference will be used as measures of effect sizes, in order to pool the data using either a random-effect model or fixed-effect model according to the heterogeneity of studies. Subgroup analysis and sensitivity analysis will be performed to explore the source of heterogeneity and evaluate the robustness of the results. We will use the Risk of Bias 2 tool and Risk of Bias In Non-Randomized Studies of Interventions tools to assess the quality of the included studies, and use the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) system to assess the certainty of evidence.Ethics and dissemination No ethical approval is required since this review is based on previously published studies. The findings of this study will be presented at international conferences or published in a peer-reviewed journal.PROSPERO registration number CRD42024558180.https://bmjopen.bmj.com/content/15/7/e090646.full |
| spellingShingle | Xin Yu Jiawei Zhang Xiangge Ren Peidong Zhao Wensheng Zhai Telitacicept for systemic lupus erythematosus: protocol of a systematic review and meta-analysis BMJ Open |
| title | Telitacicept for systemic lupus erythematosus: protocol of a systematic review and meta-analysis |
| title_full | Telitacicept for systemic lupus erythematosus: protocol of a systematic review and meta-analysis |
| title_fullStr | Telitacicept for systemic lupus erythematosus: protocol of a systematic review and meta-analysis |
| title_full_unstemmed | Telitacicept for systemic lupus erythematosus: protocol of a systematic review and meta-analysis |
| title_short | Telitacicept for systemic lupus erythematosus: protocol of a systematic review and meta-analysis |
| title_sort | telitacicept for systemic lupus erythematosus protocol of a systematic review and meta analysis |
| url | https://bmjopen.bmj.com/content/15/7/e090646.full |
| work_keys_str_mv | AT xinyu telitaciceptforsystemiclupuserythematosusprotocolofasystematicreviewandmetaanalysis AT jiaweizhang telitaciceptforsystemiclupuserythematosusprotocolofasystematicreviewandmetaanalysis AT xianggeren telitaciceptforsystemiclupuserythematosusprotocolofasystematicreviewandmetaanalysis AT peidongzhao telitaciceptforsystemiclupuserythematosusprotocolofasystematicreviewandmetaanalysis AT wenshengzhai telitaciceptforsystemiclupuserythematosusprotocolofasystematicreviewandmetaanalysis |